Creative Planning
BMRN icon

Creative Planning’s BioMarin Pharmaceuticals BMRN Stock Holding History

Creative Planning’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200
Closed -$2K – 1992
2018
Q4 		$2K Buy
+200
New +$19K ﹤0.01% 1899

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Creative Planning's BMRN Position: Q2 2026 in Review

Creative Planning increased its BioMarin Pharmaceuticals (BMRN) stake by 35% in Q2 2026, buying an estimated $2.19M and bringing the position to 153,161 shares worth $8.76M. The position accounts for 0.01% of the portfolio, ranked #981.

Creative Planning first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Creative Planning held 153,161 shares of BioMarin Pharmaceuticals worth $8.76M as of Q2 2026.
  • Creative Planning bought 40,061 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.19M.
  • BioMarin Pharmaceuticals made up 0.01% of Creative Planning's portfolio in Q2 2026, its #981 holding.
  • Creative Planning first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.